Scotiabank analyst Greg Harrison raised the firm’s price target on Vera Therapeutics (VERA) to $65 from $55 and keeps an Outperform rating on the shares. The company recently reported positive topline data from the phase 3 ORIGIN trial of atacicept, with treatment using atacicept resulting in a 42% reduction in proteinuria compared to the placebo, the analyst tells investors. The firm overall believes the company is well positioned to capture a meaningful piece of the growing IgAN despite the competitive landscape.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics: Promising Phase III Results and Strategic Positioning Justify Buy Rating
- Vera Therapeutics Secures $500M Loan Agreement
- Vera Therapeutics price target raised to $65 from $61 at Guggenheim
- Vera Therapeutics price target raised to $65 from $55 at Scotiabank
- Buy Rating for Vera Therapeutics: Promising Potential of Atacicept in IgA Nephropathy Treatment